Prospects for Durect Corp.’s Posimir (Saber-bupivacaine) dimmed dramatically with the late Thursday disclosure of a failed phase III study of the extended-release analgesic. Data from the PERSIST study, which had been designed to address a 2014 FDA complete response letter (CRL), showed a favorable trend but fell short of statistical significance on the primary endpoint of reducing pain on movement over the first 48 hours after surgery.